THE USE OF INTRAVENOUS IMMUNOGLOBULIN IN PEDIATRIC ONCOHEMATOLOGICAL PRACTICE

Q: How can I download an article?

To download an article from SID, first log in to the site, search for the article title, and click on the 'Download Article' option.

Q: How can I download an ISI article?

To download an ISI article on SID, enter the keyword or article title in the search bar, view the relevant results, click on the desired article, and select the 'Download Article' option.

Q: How can I access the SID database?

To access the SID database, visit SID.ir, create an account, and log in to access scientific resources.

Q: Is downloading articles from SID free?

Some articles on SID are available for free, while others require payment. Details are specified on the article's page.

BORANBAYEVA R.Z.; TASHENOVA G.T.; BAZARBAEVA A.A.

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Journal Paper

Paper Information

Journal: Iranian Journal of Pediatrics Year:2014 | Volume:24 | Issue:2 (SUPPLEMENT) Page(s): 25-25

Download Full-Text

View:

229

Download:

Cites:

Information Journal Paper

Title

THE USE OF INTRAVENOUS IMMUNOGLOBULIN IN PEDIATRIC ONCOHEMATOLOGICAL PRACTICE

Author(s)

BORANBAYEVA R.Z. | TASHENOVA G.T. | BAZARBAEVA A.A.

Keywords

IMMUNOGLOBULIN

ONCOHEMATOLOGY

IVIG

Abstract

Background: Presence of infectious complications in oncohematological patients significantly complicates treatment and worsens the prognosis of the underlying disease. In such situations IMMUNOGLOBULIN (IVIG) is applied. The aim of our study was to examine the efficiency of the use of IVIG in 67 children with oncohematological pathology.Methods: IVIG for the treatment of purulent-septic complications (neutropenia) used in patients with ALL - 47% (32), AML - 40% (26), histiocytosis 3% - (2), AA - 6% (4), MDS -3% (2) and PID is -1 (1, 4%), were administered a single dose of 0.2 g/kg/day, daily 1 per day, duration ranged from 1 to 7 days. The effectiveness of the drug in patients with oncohematological pathology with infectious complications was estimated on the normalization of body temperature, the results of the general analysis of peripheral blood, the general analysis of urine, triple culture of blood.Findings: Patients receiving of IVIG due to the presence of infectious complications were at various stages of therapy. Patients with acute lymphoblast leukemia received therapy program ALL-BFM-2002; patients with c myeloblastic leukemia (CML) received therapy program AML-BFM-2004; patients with Langerhans LCH-III or aplastic anemia received immunosuppressive therapy. Infectious complications in the study patients included sepsis, which took place in the form of sepsis without localized foci of infection in 15.3%, septicemia in 2.6%, sepsis with septicopyemia in 10.2%, and febrile neutropenia in 78.6%. Localization panicucci foci include bacterial carditis in 2.8%, ulcero-necrotic colitis in 8.5%, pneumonia in -10.8%, and necrotic lesions disease in 20.8%. The extension of infection occurred at the background of deep cytopenia-neutropenia (leukocytes less than 1×109, granulocytes less than 0, h). Microbial landscape of the patients was presented in 78.4% of the cases as gram-positive microorganisms and in 21.6% as gram-negative microorganisms. From blood of patients, gram-positive pathogens was seen in 55%. Among them the most oftenorganisms was Staphyloccocus aureus in 71.2%, Streptococcus Epidermidis in 66.7%, and Streptococcus in 67, 5%. Among fungal infection Candida (36.4%), Peniccillium (31.8%), Mucor (22.7%), and Aspergilius (9.1%) were seen. Mushrooms more often were detected from the blood (72.6%) than from other sources of infection. The markers to the virus Abstain-Barr (EBV) were seropositive in 48.9% of children, of Herpes virus in 93.3% of children, and of cytomegalovirus (CMV) from 80.2%. The dynamics of the temperature reaction was the following: the initial temperature of 38.4±of 0.36 Degrees; it was normalized after 1 day from the beginning of introduction of IGW treatment, in 18 patients (26%), within 3 days from the introduction of IGW in 25 patients (39%), within 5-7 days in 17 patients (25%), and was inefficient in 7 (10%) cases among whom were patients with progression of the underlying disease, recurrence ALL (1 case) and AML (2 cases), one patient with myelodysplastic resistant to therapy with manifestations of fungal sepsis not having achieved remission.Conclusion: Use of IMMUNOGLOBULIN in complex therapy of oncohematological patients, in the period of agranulocytosis has allowed to achieve improvement in 92.3% of cases, decreased the incidence and severity of infectious complications, achieved more rapid recovery of hemopoiesis, accelerated normalization of blood, and reducing interruptions in the treatment course.

Multimedia

No record.

Cites

No record.

References

No record.

Cite

APA: Copy

BORANBAYEVA, R.Z., TASHENOVA, G.T., & BAZARBAEVA, A.A.. (2014). THE USE OF INTRAVENOUS IMMUNOGLOBULIN IN PEDIATRIC ONCOHEMATOLOGICAL PRACTICE. IRANIAN JOURNAL OF PEDIATRICS, 24(2 (SUPPLEMENT)), 25-25. SID. https://sid.ir/paper/637175/en

Vancouver: Copy

BORANBAYEVA R.Z., TASHENOVA G.T., BAZARBAEVA A.A.. THE USE OF INTRAVENOUS IMMUNOGLOBULIN IN PEDIATRIC ONCOHEMATOLOGICAL PRACTICE. IRANIAN JOURNAL OF PEDIATRICS[Internet]. 2014;24(2 (SUPPLEMENT)):25-25. Available from: https://sid.ir/paper/637175/en

IEEE: Copy

R.Z. BORANBAYEVA, G.T. TASHENOVA, and A.A. BAZARBAEVA, “THE USE OF INTRAVENOUS IMMUNOGLOBULIN IN PEDIATRIC ONCOHEMATOLOGICAL PRACTICE,” IRANIAN JOURNAL OF PEDIATRICS, vol. 24, no. 2 (SUPPLEMENT), pp. 25–25, 2014, [Online]. Available: https://sid.ir/paper/637175/en

Related Journal Papers

No record.

Related Seminar Papers

No record.

Related Plans

No record.

Recommended Workshops